Patents by Inventor Benjamin Alan Katchman
Benjamin Alan Katchman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12098434Abstract: Provided herein is a method for detecting the presence of a COVID-19 virus in a human sample or an environmental sample having one or more viral and bacterial pathogens. Samples processed to obtain total nucleic acids. The nucleic acids are used as a template in a reverse transcription-amplification reaction to obtain cDNA, which is used in a PCR amplification reaction to obtain fluorescent COVID-19 virus specific amplicons. These amplicons are detected by microarray hybridization near the lowest limit of detection. Also provided is a method for detecting in addition to the COVID-19 virus, the presence of respiratory disease-causing pathogens including viruses, bacteria and fungus in a single assay using the above method.Type: GrantFiled: November 17, 2020Date of Patent: September 24, 2024Assignee: PathogenDx, Inc.Inventors: Michael Edward Hogan, Benjamin Alan Katchman, Frederick Henry Eggers, Cory Scott Newland
-
Patent number: 11920188Abstract: Provided herein is a method for detecting the presence of clade variants in the COVID-19 virus in a human sample and/or an environmental sample. Samples are processed to obtain total RNA. The RNA is used as a template in a combined reverse transcription and amplification reaction to obtain fluorescent COVID-19 virus amplicons. These amplicons are hybridized on a microarray with nucleic acid probes having sequences that discriminate among the various clade variants. The microarray is imaged to detect the clade variant. Also provided is a method of distinguishing each clade variant from others by generating an intensity distribution profile from the image, which is unique to each of the clade variants.Type: GrantFiled: May 27, 2021Date of Patent: March 5, 2024Inventors: Frederick Henry Eggers, Benjamin Alan Katchman, Fushi Wen, Candy Mavis Rivas, Cory Scott Newland, Michael Edward Hogan
-
Patent number: 11702709Abstract: Provided herein is a method for detecting the presence of clade variants in the COVID-19 virus in a human sample and/or an environmental sample. Samples are processed to obtain total RNA. The RNA is used as a template in a combined reverse transcription and amplification reaction to obtain fluorescent COVID-19 virus amplicons. These amplicons are hybridized on a microarray with nucleic acid probes having sequences that discriminate among the various clade variants. The microarray is imaged to detect the clade variant and each clade variant is distinguished from others by generating an intensity distribution profile from the image, which is unique to each of the clade variants.Type: GrantFiled: November 18, 2021Date of Patent: July 18, 2023Assignee: PathogenDx, Inc.Inventors: Frederick Henry Eggers, Benjamin Alan Katchman, Fushi Wen, Candy Mavis Rivas, Cory Scott Newland, Michael Edward Hogan
-
Patent number: 11618917Abstract: Provided herein are methods for isolating nucleic acids from intact cells in a sample of intact cells and cell free nucleic acids. The intact cells and cell free nucleic acids are captured and concentrated within the pores of a silicate matrix in a microporous silicate filter. Within the silicate matrix the cell free nucleic acids are degraded with a nuclease, the intact cells are lysed with the released DNA binding to the silicate, the nuclease treated cell free nucleic acids and contaminants from the lysed are washed from the silicate matrix and the DNA bound to the silicate is eluted therefrom to form an isolated DNA product.Type: GrantFiled: May 2, 2022Date of Patent: April 4, 2023Assignee: PathogenDx, Inc.Inventors: Michael Edward Hogan, Benjamin Alan Katchman, Candy Mavis Rivas, Yasmine Eve Baca
-
Publication number: 20220364157Abstract: Provided herein is a method for detecting the presence of a COVID-19 virus in a human sample or an environmental sample having one or more viruses and bacterial pathogens. Samples are processed to obtain total nucleic acids. A combined reverse transcription and asymmetric PCR amplification reaction is performed to obtain fluorescent labeled COVID-19 virus specific amplicons. The amplicons are detected by microarray hybridization near the lowest limit of detection. Also provided is a method for detecting concurrently with COVID-19 virus, the presence of respiratory disease-causing pathogens including viruses, bacteria and fungus in a single assay using the above method.Type: ApplicationFiled: November 17, 2020Publication date: November 17, 2022Applicant: PathogenDx, Inc.Inventors: Michael Edward Hogan, Benjamin Alan Katchman, Frederick Henry Eggers, Cory Scott Newland
-
Publication number: 20220267832Abstract: Provided herein are methods for isolating nucleic acids from intact cells in a sample of intact cells and cell free nucleic acids. The intact cells and cell free nucleic acids are captured and concentrated within the pores of a silicate matrix in a microporous silicate filter. Within the silicate matrix the cell free nucleic acids are degraded with a nuclease, the intact cells are lysed with the released DNA binding to the silicate, the nuclease treated cell free nucleic acids and contaminants from the lysed are washed from the silicate matrix and the DNA bound to the silicate is eluted therefrom to form an isolated DNA product.Type: ApplicationFiled: May 2, 2022Publication date: August 25, 2022Applicant: PathogenDx, Inc.Inventors: Michael Edward Hogan, Benjamin Alan Katchman, Candy Mavis Rivas, Yasmine Eve Baca
-
Publication number: 20220267867Abstract: Provided herein is a method for detecting the presence of clade variants in the COVID-19 virus in a human sample and/or an environmental sample. Samples are processed to obtain total RNA. The RNA is used as a template in a combined reverse transcription and amplification reaction to obtain fluorescent COVID-19 virus amplicons. These amplicons are hybridized on a microarray with nucleic acid probes having sequences that discriminate among the various clade variants. The microarray is imaged to detect the clade variant and each clade variant is distinguished from others by generating an intensity distribution profile from the image, which is unique to each of the clade variants.Type: ApplicationFiled: November 18, 2021Publication date: August 25, 2022Applicant: PathogenDx, Inc.Inventors: Frederick Henry Eggers, Benjamin Alan Katchman, Fushi Wen, Candy Mavis Rivas, Cory Scott Newland, Michael Edward Hogan
-
Publication number: 20220267829Abstract: Provided herein is a method for detecting the presence of clade variants in the COVID-19 virus in a human sample and/or an environmental sample. Samples are processed to obtain total RNA. The RNA is used as a template in a combined reverse transcription and amplification reaction to obtain fluorescent COVID-19 virus amplicons. These amplicons are hybridized on a microarray with nucleic acid probes having sequences that discriminate among the various clade variants. The microarray is imaged to detect the clade variant and each clade variant is distinguished from others by generating an intensity distribution profile from the image, which is unique to each of the clade variants. Also provided are methods for detecting and genotyping SARS-CoV-2.Type: ApplicationFiled: February 22, 2022Publication date: August 25, 2022Applicant: PathogenDx, Inc.Inventors: Frederick Henry Eggers, Benjamin Alan Katchman, Fushi Wen, Candy Mavis Rivas, Cory Scott Newland, Michael Edward Hogan
-
Publication number: 20220251635Abstract: Provided herein is a method for detecting the presence of clade variants in the COVID-19 virus in a human sample and/or an environmental sample. Samples are processed to obtain total RNA. The RNA is used as a template in a combined reverse transcription and amplification reaction to obtain fluorescent COVID-19 virus amplicons. These amplicons are hybridized on a microarray with nucleic acid probes having sequences that discriminate among the various clade variants. The microarray is imaged to detect the clade variant. Also provided is a method of distinguishing each clade variant from others by generating an intensity distribution profile from the image, which is unique to each of the clade variants.Type: ApplicationFiled: May 27, 2021Publication date: August 11, 2022Applicant: PathogenDx, Inc.Inventors: Frederick Henry Eggers, Benjamin Alan Katchman, Fushi Wen, Candy Mavis Rivas, Cory Scott Newland, Michael Edward Hogan
-
Publication number: 20220195539Abstract: Provided herein is a method for detecting the presence of a COVID-19 virus in a human sample or an environmental sample having one or more viral and bacterial pathogens. Samples processed to obtain total nucleic acids. The nucleic acids are used as a template in a reverse transcription-amplification reaction to obtain cDNA, which is used in a PCR amplification reaction to obtain fluorescent COVID-19 virus specific amplicons. These amplicons are detected by microarray hybridization near the lowest limit of detection. Also provided is a method for detecting in addition to the COVID-19 virus, the presence of respiratory disease-causing pathogens including viruses, bacteria and fungus in a single assay using the above method.Type: ApplicationFiled: November 17, 2020Publication date: June 23, 2022Applicant: PathogenDx, Inc.Inventors: Michael Edward Hogan, Benjamin Alan Katchman, Frederick Henry Eggers, Cory Scott Newland
-
Patent number: 11319582Abstract: Provided herein are methods for isolating nucleic acids from intact cells in a sample of intact cells, contamination dead cells, cell debris, and biofilm using two separation steps, either by centrifugation or filtration, performed in sequentially. Also provided is a method for isolating nucleic acids from intact cells using a first separation step followed by treatment with a nuclease and then a second separating step. Provided herein is a related method for isolating DNA from intact cells using a nuclease that produces DNA cuts on double stranded DNA, followed by a second separating step.Type: GrantFiled: March 12, 2020Date of Patent: May 3, 2022Assignee: PathogenDx, Inc.Inventors: Michael Edward Hogan, Benjamin Alan Katchman, Candy Mavis Rivas, Yasmine Eve Baca
-
Publication number: 20210017590Abstract: Provided herein are methods for isolating nucleic acids from intact cells in a sample of intact cells, contamination dead cells, cell debris, and biofilm using two separation steps, either by centrifugation or filtration, performed in sequentially. Also provided is a method for isolating nucleic acids from intact cells using a first separation step followed by treatment with a nuclease and then a second separating step. Provided herein is a related method for isolating DNA from intact cells using a nuclease that produces DNA cuts on double stranded DNA, followed by a second separating step.Type: ApplicationFiled: March 12, 2020Publication date: January 21, 2021Applicant: PathogenDx, Inc.Inventors: Michael Edward Hogan, Benjamin Alan Katchman, Candy Mavis Rivas, Yasmine Eve Baca